Dr. Ming-chu Hsu
Chairman & CEO
pharmacy
TRPMA
Taiwan
Biography
Dr. Ming-Chu Hsu is the Chairman of this company which has experience in regulatory submission with international drug approval agencies, including US FDA and China CFDA Class 1.1 IND submission and approval, and in performing multi-center, multi-national clinical trials. TaiGen drugs and patents are 100% owned by the company, with drugs in the pipeline for infectious diseases, cancer and diabetes-related complications. TaiGen has a consistently high volume of research output, with a new FDA IND submitted at least every 3-4 years.
Research Interest
administration
